Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.
作者信息
Autio Karen A, Farooki Azeez, Glezerman Ilya G, Chan Amelia, Schneider Coursen W, Barr Hallie C, Seyboth Brian M, Kampel Lewis J, Danila Daniel C, Rathkopf Dana E, Slovin Susan F, Scher Howard I, Morris Michael J
机构信息
Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
出版信息
Clin Genitourin Cancer. 2015 Aug;13(4):e305-e309. doi: 10.1016/j.clgc.2014.11.008. Epub 2014 Nov 22.
Abstract
摘要
相似文献
1
Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.
Clin Genitourin Cancer. 2015 Aug;13(4):e305-e309. doi: 10.1016/j.clgc.2014.11.008. Epub 2014 Nov 22.
2
A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
J Med Toxicol. 2016 Sep;12(3):305-8. doi: 10.1007/s13181-016-0543-y. Epub 2016 Mar 17.
3
High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
Endocr J. 2016 May 31;63(5):479-84. doi: 10.1507/endocrj.EJ16-0003. Epub 2016 Feb 9.
4
Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease.
Am J Med Sci. 2018 May;355(5):506-509. doi: 10.1016/j.amjms.2017.09.008. Epub 2017 Sep 20.
5
Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.
Prostate Cancer Prostatic Dis. 2018 Nov;21(4):461-472. doi: 10.1038/s41391-018-0060-y. Epub 2018 Jul 9.
6
Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.
Intern Med. 2017 Nov 1;56(21):2879-2882. doi: 10.2169/internalmedicine.8908-17. Epub 2017 Sep 25.
7
Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
J Oncol Pharm Pract. 2019 Dec;25(8):1846-1852. doi: 10.1177/1078155218820927. Epub 2019 Jan 7.
8
Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis.
J Oncol Pharm Pract. 2017 Apr;23(3):179-184. doi: 10.1177/1078155216628325. Epub 2016 Jun 23.
9
Excess of second tumors in denosumab-treated patients: a metabolic hypothesis.
Future Oncol. 2019 Jul;15(20):2319-2321. doi: 10.2217/fon-2019-0170. Epub 2019 Jun 25.
10
Severe and prolonged hypocalcemia after a single dose of denosumab for metastatic breast cancer with diffuse bone involvement without prior calcium/vitamin D supplementations.
J Oncol Pharm Pract. 2021 Jul;27(5):1287-1290. doi: 10.1177/1078155220964550. Epub 2020 Oct 21.
引用本文的文献
1
Bone health in cancer: perspective on the use of osteoanabolic agents.
Ther Adv Endocrinol Metab. 2025 Sep 1;16:20420188251367252. doi: 10.1177/20420188251367252. eCollection 2025.
2
Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II study.
EClinicalMedicine. 2025 Jul 4;85:103329. doi: 10.1016/j.eclinm.2025.103329. eCollection 2025 Jul.
3
Refractory Denosumab-induced Hypocalcemia in a High-risk Patient With Osteoblastic Metastatic Prostate Adenocarcinoma.
JCEM Case Rep. 2025 Jun 13;3(8):luaf121. doi: 10.1210/jcemcr/luaf121. eCollection 2025 Aug.
4
Proceedings of the 2023 Santa Fe Bone Symposium: Progress and Controversies in the Management of Patients with Skeletal Diseases.
J Clin Densitom. 2023 Oct-Dec;26(4):101432. doi: 10.1016/j.jocd.2023.101432. Epub 2023 Oct 14.
5
Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study.
BMJ. 2023 Oct 25;383:e075512. doi: 10.1136/bmj-2023-075512.
6
Lenvatinib-induced hypocalcaemia due to transient primary hypoparathyroidism.
Endocrine. 2022 Oct;78(1):197-200. doi: 10.1007/s12020-022-03139-z. Epub 2022 Jul 20.
7
Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis. 2023 Mar;26(1):126-132. doi: 10.1038/s41391-022-00573-y. Epub 2022 Jul 7.
8
Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
J Natl Cancer Inst. 2022 Mar 8;114(3):419-426. doi: 10.1093/jnci/djab196.
9
Hypocalcemia in a Patient With Metastatic Prostate Cancer From Denosumab Treatment.
Cureus. 2021 Aug 10;13(8):e17046. doi: 10.7759/cureus.17046. eCollection 2021 Aug.
10
Protective Effect of Ciclopirox against Ovariectomy-Induced Bone Loss in Mice by Suppressing Osteoclast Formation and Function.
Int J Mol Sci. 2021 Aug 2;22(15):8299. doi: 10.3390/ijms22158299.
本文引用的文献
1
Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.
Bone. 2013 Aug;55(2):305-8. doi: 10.1016/j.bone.2013.04.012. Epub 2013 Apr 25.
2
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
J Clin Oncol. 2012 Feb 10;30(5):519-24. doi: 10.1200/JCO.2011.36.5791. Epub 2012 Jan 9.
3
Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi: 10.1210/jc.2011-0385. Epub 2011 Jun 6.
4
Bisphosphonates: the first 40 years.
Bone. 2011 Jul;49(1):2-19. doi: 10.1016/j.bone.2011.04.022. Epub 2011 May 1.
5
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.
6
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
7
Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.
J Bone Miner Metab. 2010 Nov;28(6):706-12. doi: 10.1007/s00774-010-0198-8. Epub 2010 Jun 9.
8
Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid.
Prostate. 2009 May 1;69(6):624-32. doi: 10.1002/pros.20917.
9
Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
Prostate Cancer Prostatic Dis. 2009;12(1):94-9. doi: 10.1038/pcan.2008.10. Epub 2008 Mar 11.
10
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
Clin Cancer Res. 2007 Nov 1;13(21):6396-403. doi: 10.1158/1078-0432.CCR-07-1036.
Zotero 插件